ArticleJournal of global health2025
Evolution of long COVID over two years in hospitalised and non-hospitalised survivors in Bangladesh: a longitudinal cohort study.
Article in Journal of global health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Factors influencing work ability and return-to-work in individuals affected by post-COVID: a systematic review.BMC public health · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In developing settings, comparative data on COVID hospitalised survivors (HS) and non-hospitalised survivors (NHS) is scarce. We determined burdens, incidence, evolution, and associated factors of long COVID-19 over two years among these groups. Methods: We conducted a longitudinal cohort study in Dhaka, Bangladesh, and recruited confirmed COVID-19 survivors from December 2020 to May 2021 (previously reported). 346 survivors underwent in-person follow-ups at five, nine, 18 months and two years post-infection. The assessment included long COVID symptoms, cardiorespiratory function, neuropsychiatric conditions, quality of life, and laboratory tests. The outcomes included one or more symptoms and/or signs indicative of long COVID, aligning closely with the World Health Organization definition of post-COVID-19 condition. Results: Of the 346 participants, we included 326 in the analysis. 78% of HS (n/N = 171/219) and 62% of NHS (n/N = 55/89) reported at least one sequela symptom. HS had higher odds of palpitations, headaches, dizziness, sleeping difficulties, brain fog, muscle weakness, joint pain, hypertension, insulin requirement, poor quality of life, and prolonged corrected QT intervals on electrocardiogram compared to NHS at two years (95% confidence interval (CI)>1). Regarding evolution, sequelae-symptoms, neurological outcomes, restrictive spirometry findings, and electrocardiogram abnormalities remained unchanged, although psychiatric sequelae, quality of life, and exercise capacity improved in both groups. Hospital readmission rates significantly increased (P < 0.05). The incidence rates of palpitations, cough, and hypertension were higher in HS compared to NHS (95% CI>1). Two or more vaccine doses decreased the risk of respiratory (adjusted risk ratio (aRR) = 0.76; 95% CI = 0.63-0.91) and psychiatric sequelae (aRR = 0.78; 95% CI = 0.66-0.92) than one or no doses. Conclusions: COVID-19 survivors, particularly HS, experienced a higher burden of persistent symptoms and health issues two years after infection. However, vaccination significantly reduced the risk of respiratory and psychiatric outcomes. These findings highlight the importance of ongoing vaccination programs and the need for targeted rehabilitation services in low-resource settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.